Catalent extends global commercial spray drying capabilities in Europe

9 Jul 2019

Company's customers to have immediate access to Niro PSD2 and PSD4 spray driers, which are supported by dedicated clean area facilities for both solvent and aqueous processing of potent or non-potent drug formulations.

Catalent has significantly expanded the capacity of its global spray drying operations through an agreement with Sanofi Active Ingredient Solutions, an industrial platform of Sanofi, under which Sanofi will provide Catalent with access to spray drying manufacturing services for Catalent’s customers at Sanofi’s Haverhill, UK facility.

Catalent extends global commercial spray drying capabilities in Europe

This agreement immediately extends Catalent’s global spray drying offering by making available to Catalent and Catalent’s customers the dedicated use of the existing Niro PSD2 and PSD4 spray driers at the facility. These spray driers are supported by dedicated clean area facilities for both solvent and aqueous processing of potent or non-potent drug formulations as well as a secondary vacuum dryer. Catalent is now able to offer spray drying solutions from early-phase development through clinical supply and all the way to fully scaled-up commercial finished dose form manufacturing in Europe.

Under the terms of this agreement, Catalent will also have access to the facility’s integrated quality control and analytical capabilities with scientific support resources, enabling an end-to-end approach for customers.

“This agreement not only gives Catalent access to spray drying capabilities at Haverhill and its state-of-the-art equipment, but also an experienced and skilled team at the site with expertise in commercial-scale spray dried dispersions, which are frequently used today to overcome the solubility challenges with many new medicines,” said Jonathan Arnold, President of Catalent’s Oral Drug Delivery business unit.

“Sanofi Haverhill is our center of excellence for spray drying technology. The site has over a decade of experience in spray drying operations for commercial manufacture. We welcome the relationship with Catalent and are delighted that Catalent is investing in the innovation and resources at our U.K. facility,” said Philippe Clavel, Head of Sanofi Active Ingredient Solutions.

Earlier this year, Catalent announced a $40M investment in its Winchester, Kentucky facility that includes adding commercial-scale spray drying with high-potent handling capabilities, as well as other increases to the site’s capacity and its formulation and controlled-release tablet and capsule manufacturing capabilities. The Winchester facility will work alongside the Sanofi Haverhill facility to enable transfer and scale-up of spray drying programs from Catalent’s specialized early-stage clinical development sites located in San Diego, California and Nottingham, UK.

Read More

Related news

Inaugural Bio Integrates conference highlights industry's inefficiency in developing products

Inaugural Bio Integrates conference highlights industry's inefficiency in developing products

18 Jun 2019

Industry leaders give voice to issues and trends shaping the biotech sector, including the importance of collaboration.

Read more 
Lessons learned from early EU FMD adopters

Lessons learned from early EU FMD adopters

13 May 2019

Data exchange, investment costs, resources and hardware identified as some of the biggest challenges.

Read more 
Brexit's trick or treat on patient safety

Brexit's trick or treat on patient safety

29 Apr 2019

Despite a delayed Brexit, unpredictability adds further complications to the EU FMD regulation.

Read more 
Surge of Indian biosimilars market forecast in 2019

Surge of Indian biosimilars market forecast in 2019

22 Apr 2019

India predicted to be one of the world’s ‘fastest growing bio’ hubs in 2019, fuelled by new biosimilars production.

Read more 
RAPS on delayed Brexit

RAPS on delayed Brexit

26 Mar 2019

The post-Brexit regulatory environment continues to weigh heavily on the minds of regulatory professionals.

Read more 
Sizeable growth potential for global drug delivery and packaging in 2019

Sizeable growth potential for global drug delivery and packaging in 2019

19 Mar 2019

Patient-centricity, eco-friendly and smart packaging trends marked as the biggest growth drivers and innovations in 2019.

Read more 
'Tamper-evident' benefits are evident

'Tamper-evident' benefits are evident

28 Feb 2019

2019 will mark Uniplast's debut at this year's edition of CPhI Worlwide in Frankfurt, where it will showcase its expertise in plastic packaging.

Read more 
All Recipharm facilities ready for EU serialisation, regardless of Brexit

All Recipharm facilities ready for EU serialisation, regardless of Brexit

15 Feb 2019

The CDMO invested EUR 35 million into its operations and launched a 3-year programme to provide a compliant serialisation solution for its customers.

Read more 
Brexit - the EU FMD's painful problem

Brexit - the EU FMD's painful problem

7 Feb 2019

Teething problems are no stranger to the implementation of new regulations, but with the EU FMD, Brexit came like a set of wisdom teeth – late, painful and problematic.

Read more 
Pharmapack report predicts diversification of innovation leading to a rise in licensing and partnering

Pharmapack report predicts diversification of innovation leading to a rise in licensing and partnering

27 Jan 2019

New report highlights Germany, France and Switzerland as tier-one nations for ‘drug delivery innovation’, and warns the challenge will be to scale-up and approve promising prototypes.

Read more